Shared on 30 Jul 25
Fair value Decreased 30%Declining Revenues And Rising Costs Will Harm US Biotechs Future
The sharp reduction in Puma Biotechnology’s price target is primarily driven by a marked shift from modest expected revenue growth to anticipated revenue contraction, with valuation multiples increasing accordingly, resulting in a new consensus target of $3.00 (down from $4.29). What's in the News Dropped from multiple Russell growth and small-cap indices, including Russell 2000, 2500, 3000, Microcap, and Small Cap Comp Growth benchmarks.
Shared on 01 May 25
Alisertib Trials May Expand Market Reach, But NERLYNX's Revenue Decline And Competition Will Challenge Future Earnings
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 23 Apr 25
Alisertib Trials May Expand Market Reach, But NERLYNX's Revenue Decline And Competition Will Challenge Future Earnings
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 17 Apr 25
Alisertib Trials May Expand Market Reach, But NERLYNX's Revenue Decline And Competition Will Challenge Future Earnings
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Alisertib Trials May Expand Market Reach, But NERLYNX's Revenue Decline And Competition Will Challenge Future Earnings
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 02 Apr 25
Fair value Increased 0.70%Alisertib Trials May Expand Market Reach, But NERLYNX's Revenue Decline And Competition Will Challenge Future Earnings
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Alisertib Trials May Expand Market Reach, But NERLYNX's Revenue Decline And Competition Will Challenge Future Earnings
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 19 Mar 25
Fair value Decreased 0.70%Alisertib Trials May Expand Market Reach, But NERLYNX's Revenue Decline And Competition Will Challenge Future Earnings
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 11 Mar 25
Fair value Increased 11%Clinical Trials And Global Expansion Will Influence Oncology Amid Risks
AnalystConsensusTarget has increased revenue growth from -5.3% to -0.7%, decreased profit margin from 15.2% to 7.5%, increased future PE multiple from 8.8x to 16.7x and decreased discount rate from 7.7% to 6.7%.